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Human mitochondrial diseases are associated with a wide range of clinical symptoms, and those that result from mutations in mitochondrial
DNA affect at least 1 in 8500 individuals. The development of animal models that reproduce the variety of symptoms associated with this group of
complex human disorders is a major focus of current research. Drosophila represents an attractive model, in large part because of its short life
cycle, the availability of a number of powerful techniques to alter gene structure and regulation, and the presence of orthologs of many human
disease genes. We describe here Drosophila models of mitochondrial DNA depletion, deafness, encephalopathy, Freidreich's ataxia, and diseases
due to mitochondrial DNA mutations. We also describe several genetic approaches for gene manipulation in flies, including the recently developed
method of targeted mutagenesis by recombinational knock-in.
© 2006 Elsevier B.V. All rights reserved.Keywords: Drosophila; Mitochondria; Mitochondrial diseases; Gene targeting; Oxidative phosphorylation1. Introduction
The fruit fly Drosophila has played a critical role in the
origin and development of modern biology, particularly in the
field of genetics. In 1910, T. H. Morgan's experiments demon-
strating the chromosome theory of heredity initiated Drosophila
as a tool to investigate the basis of genetics and development
[1]. Features that made Drosophila useful as an animal model in
the first half of the past century are still attractive today [1,2].
These include (i) a short life cycle, (ii) the facility to feed and
maintain stocks and populations without specialized instrumen-
tation or infrastructure, (iii) the availability of non-recombino-
genic balancer chromosomes, (iv) physical mapping of genes onAbbreviations: mtDNA, mitochondrial DNA; OXPHOS, oxidative phos-
phorylation; NRG, Nuclear respiratory gene; COX, cytochrome oxidase; MDS,
mtDNA depletion syndrome; pol γ-α, DNA polymerase γ catalytic subunit; LS,
Leigh syndrome; CNS, central nervous system; FA, Friedreich's ataxia; adPEO,
autosomal dominant progressive external ophthalmoplegia; RNAi, RNA
interference; PNS, peripheral nervous system; DSB, double-strand break
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and other mutagenic agents to generate large collections of
mutant stocks and, (vi) the physical accessibility of the mech-
anosensory apparatus for experimentation. During the remain-
der of the century, new technologies were developed tomanipulate
and understand the Drosophila genome, leading to remarkable
discoveries such as the genetic control of embryonic develop-
ment by E. Lewis, C. Nüsslein-Volhard and E. Wieschaus [3].
Advances in molecular biology have allowed the generation of
transgenic flies using P-element transposons [4], the develop-
ment of the yeast UAS-GAL4-based gene overexpression sys-
tem [5] and more recently, technologies based on site specific
recombination to knock-in and knock-out specific genes, and
RNA interference (RNAi) to knock-down gene expression (for
a review, see [6]). At the same time, Drosophila melanogaster
was one of the first organisms to be sequenced in its entirety.
The first annotated sequence was published inMarch 2000, and
it has been updated regularly (http://flybase.net/annot/dmel-
release4-notes.html). The Drosophila genome contains a large
number of human orthologs, demonstrating its potential as a
model of human disease [7].
Table 1
DNA sequence elements involved in the regulated expression of essential factors
for mtDNA metabolism in Drosophila
Gene DNA sequence elements
DRE NRG EWG
pol γ-α − − +
pol γ-β + + −
mtSSB + + −
mtDNA helicase + − −
mtRNA pol − + −
TFAM + + −
mtTFB1 + − −
mtTFB2 + − −
mtTTF + − −
The proximal promoter (2 Kb) and 3′-upstream gene regions of several genes
encoding essential factors for Drosophila mtDNA metabolism have been
analyzed in silico, to search for potential binding sites for DREF, NRG and
EWG. The functional role of all DREF binding sites except that in the gene for
mtTFB1 has been demonstrated by EMSA and cell transfection analyses. [14
(mtSSB), 65 (pol γ-β), 66 (Tfam) and unpublished data from our laboratories].
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Mitochondrial biogenesis is an essential process in cell
proliferation and differentiation. It depends on the co-ordinated
expression of two genomes located in different subcellular com-
partments, the nucleus and the mitochondrion [8]. Mitochondrial
DNA (mtDNA) is a circular double-stranded DNAmolecule with
an extremely compact organization, and a gene content that iswell
conserved in the animal kingdom. It encodes 22 tRNAs, 2 rRNAs
and 13 polypeptides, all of which are components of the oxidative
phosphorylation system (OXPHOS). The rest of the subunits of
theOXPHOS system (about 90) and all of the proteins involved in
the maintenance and expression of mtDNA, and all other mito-
chondrial functions, are encoded in nuclear DNA [8].
In the last few years, several mammalian transcriptional reg-
ulators have been characterized that control the expression of both
nuclear and mitochondrial genes, and therefore play a critical role
in intergenomic communication [9]. Extracellular signals induce
expression of PGC-1 family coactivators, which in cooperation
with specific transcription factors (mainly Nuclear Respiratory
Factors, NRF-1 and NRF-2), have been found to regulate the
expression of many genes involved in mitochondrial biogenesis.
These include structural subunits of the OXPHOS system, en-
zymes involved in intermediary metabolism, and several factors
involved in mtDNA maintenance and transcription (reviewed in
[10]). A similar framework to explain the integrated control of
Drosophila mitochondrial gene expression has not been identi-
fied. The ortholog of nrf-1 in Drosophila, erect wing, is essential
for neurogenesis and myogenesis [11], but it has not been linked
directly to regulation ofmitochondrial gene expression. Thus, it is
presently unknown if the circuitry that coordinates mitochondrial
biogenesis at the transcriptional level in mammals is conserved in
Drosophila.
Our laboratories and others have carried out a systematic
characterization of the promoter regions ofDrosophila genes en-
coding factors involved in mtDNA replication, maintenance and
transcription [reviewed in [12]). To date, these include the genes
encoding the two subunits of DNA polymerase γ (α and β) [13],
mtSSB [14], mtDNA helicase (L.S. Kaguni, unpublished data),
mtRNA polymerase (R. Garesse, unpublished data), TFAM
[15], mtTFB1 [16], mtTFB2 [17] andDmTTF [18] (Table 1).We
have found that the expression of most of these genes is regu-
lated by DREF, a transcription factor that also regulates the
expression of genes involved in nuclear DNA replication and
cell cycle control, including the catalytic subunit of DNA poly-
merase α, proliferating cell nuclear antigen, cyclin A and E2F
[12]. In addition, a recently identified conserved sequence ele-
ment (RTTAYRTAAY), designated as the Nuclear Respiratory
Gene element (NRG), is located downstream of the transcrip-
tional initiation site of a high proportion of nuclear genes en-
coding mitochondrial proteins [19]. Although there are no
functional studies and the transcription factors that recognize the
NRG site have yet to be identified, this element represents a good
candidate for involvement in the coordinate response of genes
involved in energy production in Drosophila, perhaps in com-
bination with DREF. In support of this hypothesis, several of the
genes encoding factors of the Drosophila mtDNA replicationand transcription machineries contain both DRE and NRG
sites.
To begin to understand the regulation of mitochondrial bio-
genesis during embryonic development, we have studied by in
situ hybridization and immunostaining the spatio-temporal ex-
pression pattern of genes encoding mtDNA replication factors
as markers of mitochondrial proliferation, and those encod-
ing structural components of the OXPHOS system as markers
of mitochondrial differentiation. We have found that genes in-
volved in mtDNA metabolism are highly expressed in the gut,
and in some cases in additional cellular domains of the embryo.
OXPHOS genes are also highly expressed in the gut, but are
also expressed at high levels in other tissues including the me-
soderm (M.A. Fernández-Moreno and R. Garesse, unpublished
data). These results indicate that mitochondrial proliferation and
differentiation are not strictly coupled during development.
Interestingly, the molecular characterization of bonsaimutants
has also revealed that the gut is extremely active in mitochondrial
biogenesis duringDrosophila development [20]. The Bonsai pro-
tein is highly expressed in the gut, localizes to mitochondria and
shows strong homology to prokaryotic ribosomal protein S15,
suggesting a role in mitochondrial translation. However, the
precise role of Bonsai in mitochondrial function remains to be
determined.
3. Drosophila as an animal model to study human
mitochondrial diseases
Drosophila provides a useful model for studying several
complex biological processes because it is ideally tractable at
the genetic, biochemical, molecular and physiological levels. It
has served as a model in studies of development and differenti-
ation [3], aging [21], cell cycle [22], transcriptional and transla-
tional control [23], signaling pathways [24], response to hyp-
oxia [25], sensorial perception [26], and circadian rhythms [27].
In addition, the presence in Drosophila of orthologs of genes
involved in human diseases has spawned interest in using it to
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therapies. Representative research using Drosophila has been
focused on neurodegenerative diseases [7,28], cancer [29], car-
diac pathologies [30], age-associated dysfunction [31], sen-
sitivity to pollutants [32], and more recently on mitochondrial
diseases (see below).
Mitochondrial diseases, mainly due to the alteration of
OXPHOS functions, are associated with a wide range of clinical
symptoms, especially those in neurodegenerative disorders, such
as blindness, deafness, dementia, movement disorders, ataxia,
corea, and encephalopathies [33,34]. Mitochondrial defects are
also associated with muscular weakness, cardiac failure, diabetes,
renal dysfunction and hepatic disease. The clinical and genetic
diversity of mitochondrial pathologies makes it difficult to esti-
mate their incidence in the population, which in composite, is
considered relatively high. The alteration of OXPHOS function
caused by known mutations in mtDNA affects at least 1 in 8500
people. One of the main objectives in understanding the phy-
siopathology of mitochondrial diseases is to create amenable
animal models that reproduce the variety of symptoms associated
with this group of complex human disorders. Although a great
effort is currently focused on developing mammalian models of
human mitochondrial pathologies, Drosophila emerges as an
attractive, tractable alternative.
3.1. mtDNA depletion
mtDNA depletion syndrome (MDS) is caused by a defect in
intergenomic communication that results in decreased mtDNA
content (i.e., a low mtDNA/ nDNA ratio). Children usually pre-
sent with hypotonia, lactic acidosis and elevated serum creatine
kinase. Some also have severe hepatopathy or renal involvement
mimicking de Toni–Fanconi syndrome. The symptoms can also
involve multiple systems affecting the muscle. Mutations in the
genes encoding the mitochondrial deoxyguanosine and deox-
ythymidine kinases are associated with the hepatocerebral and
the myopathic forms of MDS [35]. In addition, preliminary
studies have also shown a deficient activity of DNA polymerase
γ in tissues of patients suffering MDS [36].
Our laboratories have used the UAS-GAL4 system to alter
the level of mtDNA in the fly. Overexpression of a wild-type
version of the catalytic subunit of mitochondrial DNA poly-
merase (pol γ-α) interferes with the process of mtDNA rep-
lication and produces a significant decrease in the amount of
mtDNA [37]. We have analyzed the consequences of the
mtDNA depletion in the whole animal, and specifically in two
tissues affected in MDS patients, muscle and nervous system.
mtDNA depletion resulting from constitutive overexpression is
lethal at the pupal stage, a phenotype that is also observed upon
specific overexpression in the muscle. Interestingly, the in-
duction of mtDNA depletion in the nervous system is not lethal.
The main phenotype detected in adults is an increase in the
population mortality rate, and a moderate but significant in-
crease in apoptosis in the larval brain, which likely contributes
to the phenotype. This model presents the opportunity to char-
acterize the molecular and metabolic responses of various
tissues to mtDNA depletion, and to develop methods that alle-viate it. At the same time, recognizing that overexpression of the
wild-type catalytic subunit may generate secondary effects not
related directly to the mtDNA depletion, we are complementing
these studies with the introduction of specific mtDNA mu-
tations in the pol γ-α gene by homologous recombination (see
below).
3.2. Mitochondrial deafness
The Drosophila mutant technical knock-out, tko, carries a
point mutation affecting a phylogenetically conserved residue in
the nuclear gene encoding the mitochondrial ribosomal protein
S12 (MRPS12). This behavioural mutant exhibits developmen-
tal retardation at the larval stage, bang sensitivity, defective
response to sound, quantitatively reduced mitochondrial trans-
lational capacity and impaired male courtship [38]. The primary
biochemical defect is a decrease in OXPHOS and ATP synthase
activities in mitochondria. tko mutants possess various features
of mitochondrial disorders in humans, and these phenotypes are
reverted by transgenic expression of a wild-type copy of the tko
gene. The transgenic reversion analysis revealed critical steps
and cell types that were responsible for the disease-like pheno-
type [39]. Furthermore, inbreeding of mutant lines resulted in
a systematic improvement of the phenotypic outcome. These
features have made the tko mutant a suitable model for many
forms of human mitochondrial disease that are characterized by
a reduction in the mitochondrial respiratory capacity and a
generalized OXPHOS deficiency and in particular, for senso-
rineural deafness.
3.3. Mitochondrial encephalopathy
Mutations in mtDNA and in nuclear-encoded mitochondrial
proteins cause a group of devastating encephalomyopathies with
complex clinical features [40]. Leigh syndrome (LS) is the most
common infantile mitochondrial encephalopathy and is charac-
terized by symmetric necrotic lesions in the brainstem,
diencephalon and basal ganglia. Symptoms usually include nys-
tagmus, ataxia, dystonia, hypotonia and optic atrophy. Although
the cause of the disease is genetically heterogeneous, mutations in
the surf-1 gene are the singlemost prevalent cause of LS [41]. The
surf-1 gene is highly conserved from prokaryotes to humans, and
is expressed ubiquitously in human tissues, albeit at higher levels
in aerobic tissues. It encodes a 31 kDa protein located in the inner
mitochondrial membrane. Previous studies in human cells [42],
mice [43] and yeast [44] showed that Surf-1 is involved in COX
complex assembly. Nonetheless, the molecular mechanism
leading to the pathogenic course of LS is not fully understood.
Zordan and co-workers performed a functional knock-down
of Surf-1 in Drosophila using an RNAi strategy [45]. Post-
transcriptional gene silencing was induced by GAL4-mediated
expression of an UAS inverted-repeat transgene. Ubiquitous
silencing results in severely impaired development. Larvae are
smaller and exhibit profound alterations in spontaneous and
light-induced locomotion. Most individuals die before enter-
ing pupariation. Notably, behavioural and electrophysiological
abnormalities were found not to be due to structural defects, but
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was silenced exclusively in the central nervous system (CNS),
individuals developed to adulthood and exhibited altered mi-
tochondria in larval muscles, and decreased COX activity in
cephalic sections. Because both development and metamorpho-
sis are high energy-requiring processes, a defect in respiration and
ATP synthesis may be responsible for the developmental delay
and the late larval lethality observed in Surf-1-deficient larvae.
The results obtained in the Drosophila model suggest important
functions for Surf-1 in COX activity, and establish a critical role
for mitochondrial energy pathways in organogenesis, develop-
ment and CNS function that are likely to be similar in humans.
3.4. Friedreich ataxia
Friedreich ataxia (FA) is an inherited recessive neurodegen-
erative disorder associated with a genetic insufficiency of frataxin
in humans [46]. Frataxin is encoded by the FRDA gene and has a
predicted size of 210 amino acids [47]. It is a mitochondrial iron
chaperone that plays a critical role in iron storage, cellular iron
homeostasis and biogenesis of Fe–S clusters. As an iron binding
protein, frataxin prevents Fe+2 from generating toxic hydroxyl
radicals inside the mitochondrial matrix.
Most FA patients are homozygous for a GAA triplet repeat
expansion in the first intron of the FRDA gene. While normal
chromosomes contain up to 40 repeats, FA chromosomes har-
bor between 90 and 1000 triplets. Due to the meiotic and mitotic
instability of the expanded alleles, FA patients have insufficient
frataxin levels, resulting in iron accumulation in mitochondria
and dysfunctional iron-containing proteins, specifically aconi-
tase and the OXPHOS complexes. The peripheral nervous sys-
tem (PNS) and heart are among the most severely affected
tissues. Hence, FA is characterized by progressive neurological
disability and heart abnormalities. The age of onset may vary
from infancy to adulthood, but FA usually appears during child-
hood. Variations in symptoms and age of onset suggest that other
factors in addition to the degree of triplet expansion influence
disease progression, and there is currently no effective therapy
for this devastating disease.
Frataxin is highly conserved throughout evolution. Orthologs
have been identified in mammals, invertebrates, yeast and plants,
and several models have already been used to gain insight into
the functions of frataxin and its related disease. Previous studies
in yeast revealed that deletion of YFH1, the frataxin homolog,
produces iron accumulation in mitochondria and a progressive
loss of respiratory competence and mtDNA. As a result,ΔYFH1
strains exhibit permanent mitochondrial damage and dysfunction
[48]. Cell differentiation experiments performed in mouse cell
lines demonstrated that frataxin is essential for development of
neural lineages [49]. Although mouse models for FA showed
early embryonic lethality [50] conditional inactivation of the
mouse FA gene led to cardiomyopathy, sensory nerve defects and
Fe–S enzyme deficiency [51].
A RNAi strategy was used in Drosophila to suppress pro-
duction of the frataxin homolog (DFH) in a global or tissue-
specific manner [52]. The main advantage in the Drosophila
system as compared to other eukaryotic models is that invertedrepeat transgenes used in RNAi reduce rather than totally eli-
minate the corresponding protein. Thus, the Drosophila model
mimics more accurately the genetic origin of FA, which arises
from a decrease rather than a complete loss of frataxin. Fur-
thermore, the fly model also circumvents the early embryonic
lethality reported in frataxin-null mice. Systemic suppression of
the dfh gene led to large, long-lived larvae that showed dimin-
ished iron cofactor-dependent enzyme activity, and increased
susceptibility to iron toxicity. Because prolonged larval devel-
opment and failure to initiate and complete metamorphosis are
common features of Drosophila mutants defective in mtDNA
maintenance, observations from this model prompted the
hypothesis that DFH depletion may lead to increased mtDNA
damage. Whereas silencing of the dfh gene in motor neurons
had no deleterious effect, silencing in the PNS resulted in nor-
mal larval development but a reduced adult life span. Over-
expression of primary ROS-metabolizing enzymes, such as
SOD1, SOD2 and catalase in combination with silencing of the
dfh gene did not improve the phenotype, suggesting that oxi-
dative stress is not a major contributor.
The Drosophila model of FA is further validated by the fact
that the vulnerability of the PNS to frataxin depletion is con-
served across the animal kingdom. Because a DFH deficiency
produces a robust phenotype in Drosophila, the fly model may
aid in the identification of factors that alleviate FA symptoms,
and the development of novel treatment strategies.
3.5. Mitochondrial diseases caused by mtDNA mutations
Point mutations in mtDNA are associated with a wide range
of severe mitochondrial diseases, including a number of
encephalomyopathies with complex clinical features [33].
Although some of the mutations have been characterized in
cybrid cell lines, and demonstrated to produce a clear
mitochondrial impairment, it has not been possible to study
the consequences of the mutations in animal model systems
because of the currently inability to transform mitochondria with
exogenous DNA. Very recently, the first pathogenic mtDNA
mutation in an intact animal was reported in Drosophila, a G–A
transition that affects an evolutionarily conserved amino acid
residue in the ATP6 gene [53]. Point mutations in the human
ATP6 gene cause neuropathy, ataxia, and retinitis pigmentosa
(NARP), maternally inherited Leigh's syndrome (MILS) and
familial bilateral striatal necrosis (FBSN) [33]. Notably, the G–A
transition in the ATP6 gene was found in virtually homoplasmic
levels in a Drosophila sesB stock that carries a mutation in the
ANT1 gene, which is associated with autosomal dominant
progressive external ophtalmoplegia (adPEO) in humans [54].
Patients with PEO are predisposed to secondary mtDNA
mutations, and it is thus possible that a similar mutator effect
has occurred in Drosophila. The ATP6 mutation inhibits
significantly the activity of ATP synthase, but surprisingly does
not affect the respiration rate, and therefore the mitochondria are
uncoupled. Most interestingly, Drosophila ATP6 mutants have a
short life span, locomotion impairment and myodegeneration that
are strictly progressive, a situation similar to human mitochon-
drial encephalomyopathy of mitochondrial origin. Although the
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dysfunction was apparent.
4. New perspectives for gene manipulation in Drosophila
Until recently, Drosophila models used in the study of
mitochondrial dysfunction were based on the analysis of
mutants generated by random mutagenic screens, or by gene
silencing by RNAi that is based on P-element transgenesis.
One of the main advantages of the fly system is the UAS–
GAL4 binary system, which can be exploited to knockdown
a target gene under the control of alternative promoters, thus
restricting silencing to a desired spatio-temporal pattern.
More recently, new technologies for gene manipulation in
Drosophila have been expanded to include new genome
integration methods based on bacteriophage ϕC31 or
piggybacks that show much less insertional specificity than
P-elements [6]. Despite these advances, the study of specific
mutations associated with human diseases has been ham-
pered by the lack of gene targeting techniques, one of the
main limitations in working with Drosophila. Golic and co-Fig. 1. Gene targeting inDrosophila. A, Ends-in technique and the elements of the don
SceI generates the recombinogenic template, which produces the duplication at the tar
The double-strand break caused by endonuclease I-CreI induces the second recomb
alleles of the target gene. C, Ends-out technique. FLP and I-SceI generate a linear Dworkers have recently circumvented this drawback with the
development of efficient homologous recombination-based
methods [55]. Any endogenous locus can be replaced or
deleted by the expression of a site-specific recombinase and
a site-specific nuclease, taking advantage of the fact that
double-strand breaks (DSB) in Drosophila DNA are
recombinogenic. There are currently two techniques that
use homologous recombination for gene replacement, “Ends-
in” and “Ends-out”. These systems have similar efficiencies
but present different advantages and disadvantages.
4.1. Ends-in
The Ends-in approach first introduces a version of the gene
containing the mutation of interest in tandem with the endo-
genous allele, and then removes one of the copies leaving only
the mutated or wild-type allele in the chromosome. The main
advantage of this approach is that intact alleles can be recovered
that harbor the desired mutation.
The Ends-in targeting technique is executed in three steps
(Fig. 1A and B). First, a P-element construct is generated thator construct. After transgenesis the combined action of FLP and endonuclease I-
get gene locus by homologous recombination. B, reduction of target gene repeats.
ination. Ends-in targeting introduces a point mutation (green dot) in one of the
NA molecule that undergoes homologous recombination with the target gene.
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gous to the target gene containing the specific mutation(s), two
FLP Recombination Target (FRT) sequences, an I-SceI en-
donuclease recognition site, an I-CreI endonuclease recognition
site, and a marker gene, usually white+. P-element transfor-
mation is performed by standard methods [4]. The range of total
local homology that has led to successful targeting is between
2 kb and 9 kb, with N4 kb utilized in most cases [56]. Second, a
series of crosses between the transgenic flies carrying the donor
element with fly stocks harboring FLP and I-SceI transgenes
allow the expression of the enzymes by heat shock induction,
thus generating the recombinogenic donor, and inducing target-
ed homologous recombination. Homologous recombination ge-
nerates a typical structure in which the endogenous and themutant
copies of the gene flank the marker gene at the target locus. The
wild-type–white+-mutant gene structure is not expected to mani-
fest a phenotype until reduction. Finally, a second homologous
recombination event resulting from expression of the endonucle-
ase I-CreI removes one copy of the gene, the wild-type or the
mutant, and thewhitemarker. This results in the replacement of the
endogenous copy with a version containing the specific mutation
without any other alterations in the genome. To date, this novel
method has been used to generate mutant alleles of several endo-
genous Drosophila genes [57].
4.2. Ends-out
Ends-out targeting is the most frequently used method in mice
and yeast. This technique starts with a different donor construct
structure, and also differs from Ends-in in the position of the
specific-site endonuclease cleavage sites (Fig. 1C). The double-
stranded breakage occurs at the outer ends of donor DNA. TheFig. 2. Pol γ knock-in inDrosophila. Approximately 12 kb of DNA from theD. melan
the vector pBluescript. For simplicity, only the pol γ-α and pol γ-β genes are shown
genes, and this construct was used to generate specific mutations (boxed in yellow) in
and polymerase (A, B and C) active site motifs are indicated by boxes. Each of the m
orientation of the inserted DNAwas confirmed by KpnI digestion. The main features
(red box), I-CreI recognition site (blue box), NotI recognition sites (thin arrows).process of Ends-out targeting is similar to Ends-in targeting;
through the action of FLP and I-SceI, a linear DNA extrachro-
mosomal donor fragment is generated, and it is targeted to the
endogenous allele by homologous recombination. Two of the
advantages of the Ends-out method are that the target gene can be
replaced without the involvement of a tandem duplication, thus
generating a knock-in or knock-out in one step. In addition, the
donor construct is easier to make than in Ends-in. The disad-
vantage of this technique is that the end product leaves exogenous
sequence at the altered locus, usually the marker gene [58]. Ends-
out gene targeting has been used successfully to target yellow, the
myocardin-related transcription factor DMRTF, and the odorant-
receptor gene, Or83b (reviewed in [6]).
5. Current models of mitochondrial diseases in flies
In our laboratories, we are developing a Drosophila model of
mitochondrial pathology associated with pol γ mutations using
the knock-in technology. Even though we have been successful in
circumventing by low-level expression the deleterious phenotypes
engendered with high-level overexpression of wild-type pol γ-α
we recognize that potential problems may result from develop-
mental and spatial mis-expression of a transgene. Thus, we have
altered our strategy for mutagenesis inDrosophila to use targeted
gene replacement by homologous recombination (Fig. 2). Our
objective has been to introduce in Drosophila versions of the pol
γ-α gene that are associated with PEO in humans, and to examine
the effects of several mutations in theDrosophila pol γ-α and pol
γ-β genes for which disease phenotypes have not yet been
reported in humans. Of the 30 different mutations that have been
identified in the human pol γ-α gene [59], approximately half are
in strictly conserved positions in the orthologous gene inogaster pol γ cluster genomic region [60] was amplified by PCR and cloned into
schematically (arrows). The I-SceI recognition site was introduced between the
the pol γ-α or pol γ-β coding regions. The conserved exonuclease (I, II and III),
odified genomic DNAs was cloned into the NotI site of the pTV2 vector, and the
of the pTV2 vector are indicated as follows: FRTs (arrows), white + marker gene
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and Y873C in Drosophila), which map within the conserved γ1
element in the spacer region and the pol domain, respectively, and
for which we and others have already evaluated the biochemical
defects upon recombinant expression in the baculovirus system
[60–63]. We have also selected the Drosophila γ3 spacer-region
mutation F578A, for which we have defined the biochemical
defects [64]. In addition, we have introduced a double mutation
(D185A and D263A) within two active site aspartate residues in
the exonuclease domain, which we have shown to cause deve-
lopmental defects, delays and arrest, and to limit life span when it
is expressed at a low level using the UAS-GAL4 system in trans-
genic animals. Finally, we took advantage of our prior discovery
that the two subunits of Drosophila pol γ map within a compact
gene cluster [13] to generate a fragment containing∼12 kb donor
homology that carries both the pol γ-α and -β genes, with the I-
SceI site introduced between them. This allowed us to introduce
specific amino acid substitutions in both pol γ-α and -β in a single
recombinant donor construct. After homologous recombination,
the expected product is a tandem partial duplication of the target
genome sequence, with one copy containing the desired pol γ-α
mutation and the other copy containing the desired pol γ-βmuta-
tion. As a result, we have also introduced threemutations in the C-
terminal region of the Drosophila accessory subunit gene, which
we have shown to be deleterious in our biochemical analysis of
human pol γ-β.
Our immediate goals will be to evaluate these models using
established protocols in Drosophila to analyze mtDNA content
and integrity, respiratory chain complex activity, mitochon-
drial distribution and function, apoptotic signaling and
importantly, larval and adult behaviour. We expect to establish
an experimental system of mtDNA replication failure that is
analogous to that associated with human pathologies and in
doing so, we will establish a direct correlation between the
defect(s) that the mutants exhibit in our biochemical assays
and their phenotypic effects in vivo. We anticipate that this will
set the stage for us to use the power of Drosophila molecular
genetics to search for factors that modulate the phenotype,
either augmenting or ameliorating it.
6. Concluding remarks
Although tissues requiring high oxidative metabolism are
affected most severely in mitochondrial disorders, specific
tissue involvement varies considerably. In order to develop
therapies for these diseases, it is necessary to determine both
the cellular processes and the tissues that are altered by in-
sufficient energy supply. Drosophila models can help us to
understand common aspects of these pathologies because they
enable the identification of critical times, cell types and tissues
that account for the disease-like phenotypes. Global transcrip-
tional analysis of these models has already revealed many sets
of genes, including those related to stress responses and
metabolism, which are systematically up- or down-regulated
according to the degree of the mitochondrial dysfunction. The
ultimate aim of such transcriptomic approaches is to identify
potential pharmacological targets in mitochondrial disease.Because the recent development of efficient gene targeting
methods has paved the way for the introduction of specific
mutations responsible for human mitochondrial diseases, Dro-
sophila offers substantial promise for understanding the patho-
genic mechanisms of this devastating group of diseases.Acknowledgements
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